Delcath (DCTH) plummets 15.3% after saying that the FDA has accepted its Chemosat delivery...

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

Delcath (DCTH) plummets 15.3% after saying that the FDA has accepted its Chemosat delivery system to treat a form of liver cancer for a standard review and not a priority one, as the company requested. That means that the agency has up to ten months to decide whether to approve the Chemosat system rather than six, as per a priority assessment. (PR)